Oct 27, 2010 by Ralph CasaleCompanion Diagnostics in Cancer Drug DevelopmentDiagnostic companies partnering with drug developers can make for an attractive investment segment.
Oct 26, 2010 by Ralph CasaleWhere We Are in the War on CancerA recap of Xconomy's recent event, "Boston's War on Cancer."
Oct 26, 2010 by Ralph CasaleThe Changing Landscape of Pharmaceutical InformationBoston's War on Cancer examines the state and direction of cancer therapy research.
Oct 25, 2010 by Ralph CasaleThe State of Oncology and the Future for Biotech InvestorsMillennium CEO Dr. Deborah Dunsire talks to the Fool's Ralph Casale about the state of the industry.
Oct 25, 2010 by Ralph CasaleThe War on Cancer: A Long and Ongoing StruggleNotes from Xconomy's "War on Cancer" biotechnology forum.
Mar 30, 2007 by Ralph CasaleAnother Genetic Sequencer Gobbled UpRoche buys out second-generation sequencer 454 Life Scienes.
Mar 27, 2007 by Ralph CasaleBeckman-Coulter Gets DiagnosticA look at Beckman-coulter's acquisition of Biosite.
Feb 12, 2007 by Ralph CasaleAffymetrix Expresses ProfitsNew diagnostics products make for a bright 2007.
Jan 25, 2007 by Ralph CasaleVarian Beams In ResultsThe medical equipment manufacturer has both causes for concern and reasons to be positive.
Jan 23, 2007 by Ralph CasaleWin-Win for Abbott and GE?Abbott trades its medical diagnostics segment for cold hard cash.
Jan 19, 2007 by Ralph CasaleThe Best Drug Stock for 2007: GlaxoSmithKlineGlaxo's an all-around winner for the year to come.
Jan 4, 2007 by Ralph CasalePicks and Shovels of BiotechnologyCAPS players rate the best companies supporting the biotechnology and pharmaceutical industries.
Nov 17, 2006 by Ralph CasaleNot Your Father's Index FundsFundamental indexing offers a new twist on the tried-and-true strategy of index investing.
Nov 6, 2006 by Ralph CasaleValidation for a Biotechnology Firm?How Merck's bid to buy a competitor could affect Alnylam Pharmaceuticals.
